Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latozinemab in C9orf72-Associated ALS
NCT05053035Phase 2Terminated
- Sponsor
- Alector
- Start
- Sep 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing AL001 with Placebo (2 arms). Primary endpoints: Number of Subjects With Adverse Events at 24 weeks, Immunogenicity of AL001 at Week 24 and 4 more. Started Sep 2021; status: terminated.
02
Drugs
latozinemab
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05053035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053035.